- Report
- April 2023
- 120 Pages
Global
From €4592EUR$4,750USD£3,945GBP
- Report
- April 2021
- 50 Pages
China
From €2514EUR$2,600USD£2,159GBP
- Report
- March 2018
- 35 Pages
Global
From €9668EUR$10,000USD£8,304GBP
Eliquis is a hematological drug used to treat and prevent blood clots. It is a direct factor Xa inhibitor, meaning it works by blocking the action of factor Xa, a protein involved in the clotting process. Eliquis is used to reduce the risk of stroke and systemic embolism in people with non-valvular atrial fibrillation, to treat deep vein thrombosis and pulmonary embolism, and to reduce the risk of recurrent deep vein thrombosis and pulmonary embolism. It is also used to prevent venous thromboembolism in people undergoing hip or knee replacement surgery.
Eliquis is marketed by Bristol-Myers Squibb and Pfizer. Other companies in the market include Bayer, Daiichi Sankyo, and Boehringer Ingelheim. Show Less Read more